Nevro Stock Forecast, Price & News

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 2 sell ratings, 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Nevro stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View analyst ratings for Nevro or view top-rated stocks.

14 equities research analysts have issued twelve-month target prices for Nevro's shares. Their NVRO stock forecasts range from $55.00 to $150.00. On average, they predict Nevro's stock price to reach $85.00 in the next twelve months. This suggests a possible upside of 72.7% from the stock's current price.
View analysts' price targets for Nevro or view top-rated stocks among Wall Street analysts.

Nevro's stock was trading at $81.07 on January 1st, 2022. Since then, NVRO shares have decreased by 39.3% and is now trading at $49.21.
View the best growth stocks for 2022 here.

Nevro is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Nevro.

Nevro Corp. (NYSE:NVRO) released its quarterly earnings data on Wednesday, May, 4th. The medical equipment provider reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.11) by $0.13. The medical equipment provider earned $87.40 million during the quarter, compared to the consensus estimate of $86.19 million. Nevro had a negative net margin of 35.25% and a negative trailing twelve-month return on equity of 38.02%. The firm's quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.85) EPS.
View Nevro's earnings history.

Nevro issued an update on its second quarter 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $103.00 million-$106.00 million, compared to the consensus revenue estimate of $104.36 million.

9 employees have rated Nevro CEO D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among Nevro's employees.

Some companies that are related to Nevro include Globus Medical (GMED), Inspire Medical Systems (INSP), Penumbra (PEN), Integra LifeSciences (IART), ICU Medical (ICUI), Tandem Diabetes Care (TNDM), Inari Medical (NARI), iRhythm Technologies (IRTC), Haemonetics (HAE), Merit Medical Systems (MMSI), Axonics (AXNX), NuVasive (NUVA), Glaukos (GKOS), Beauty Health (SKIN) and AtriCure (ATRC).
View all of NVRO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.38%), Vanguard Group Inc. (9.22%), Wellington Management Group LLP (5.10%), Invesco Ltd. (2.95%), State Street Corp (2.28%) and Brown Advisory Inc. (1.74%). Company insiders that own Nevro stock include Andrew H Galligan, D Keith Grossman, Doug Alleavitch, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends for Nevro.

NVRO stock was sold by a variety of institutional investors in the last quarter, including Sei Investments Co., Jennison Associates LLC, Massachusetts Financial Services Co. MA, Dimensional Fund Advisors LP, Canada Pension Plan Investment Board, Assenagon Asset Management S.A., Engineers Gate Manager LP, and Russell Investments Group Ltd.. Company insiders that have sold Nevro company stock in the last two years include Leslie Stretch, Michael F Demane, Niamh Louise Pellegrini, and Shawn Mccormick.
View insider buying and selling activity for Nevro or view top insider-selling stocks.

NVRO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Wellington Management Group LLP, Federated Hermes Inc., Woodline Partners LP, Brown Advisory Inc., Victory Capital Management Inc., Vanguard Group Inc., and Capital Fund Management S.A.. Company insiders that have bought Nevro stock in the last two years include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, and Kevin C Oboyle.
View insider buying and selling activity for Nevro or or view top insider-buying stocks.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVRO stock can currently be purchased for approximately $49.21.

Nevro (NYSE:NVRO) has a market capitalization of $1.74 billion and generates $386.90 million in revenue each year. The medical equipment provider earns $-131.36 million in net income (profit) each year or ($3.900010) on an earnings per share basis.

Nevro employs 945 workers across the globe.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The official website for Nevro is www.nevro.com. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at [email protected].